Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.
Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma. Blood Neoplasia. 2025 Nov; 2(4):100124.